Matching Placebo (IV)

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

HealthyHealthy Volunteer

Phase 1

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

CompletedNCT05293678

Regeneron PharmaceuticalsHealthy

Start: 2022-04-12End: 2023-01-26Updated: 2023-02-23

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

CompletedNCT05603195

Regeneron PharmaceuticalsHealthy Volunteer

Start: 2023-01-12End: 2024-09-17Updated: 2024-10-01

Related Papers

Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)

Blood2026-06-11

PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION

Bleeding Thrombosis and Vascular Biology2026-04-16

PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508<SUP>CAT</SUP>

Bleeding Thrombosis and Vascular Biology2026-04-16